StockMarketWire.com - Tiziana Life Sciences reported positive clinical trial data for a treatment for hepatocellular carcinoma, or HCC.

The additional Phase 2a clinical data exhibited 'impressive clinical activity' of Milciclib monotherapy in patients with advanced Sorafenib-resistant or -intolerant patients with unresectable or metastatic HCC.

The trial enrolled 31 patients in Italy, Greece and Israel, of which 28 patients were evaluable.

While the primary endpoint of this study was overall safety, secondary endpoints were also evaluated.

Seventeen of the 28 evaluable patients showed 'stable disease', while one showed 'partial response'.

Eighteen showed 'clinical benefit rate'.

'The current therapies for HCC are often associated with severe toxicities, resulting in poor patient compliance,' chairman Gabriele Cerrone said.

'Hence, there is an immediate need for efficacious therapies that will not compromise patients' quality of life.'

'We believe that the overall safety profile of Milciclib is an important competitive advantage over existing therapies currently used for treating HCC.'

'The positive clinical activity and tolerability data of Milciclib in Sorafenib-resistant and advanced HCC patients are very encouraging and provides affirmation for continued development of Milciclib, either as monotherapy or combination therapy.'


At 8:13am: [LON:TILS] Tiziana Life Sciences Plc share price was +12p at 60p



Story provided by StockMarketWire.com